SARS-CoV-2 Vaccination and Protection Against Clinical Disease: A Retrospective Study, Bouches-du-Rhône District, Southern France, 2021.
COVID-19
SARS-CoV-2
death
hospitalization
intensive care
protective effect
vaccine
Journal
Frontiers in microbiology
ISSN: 1664-302X
Titre abrégé: Front Microbiol
Pays: Switzerland
ID NLM: 101548977
Informations de publication
Date de publication:
2021
2021
Historique:
received:
17
10
2021
accepted:
15
12
2021
entrez:
4
2
2022
pubmed:
5
2
2022
medline:
5
2
2022
Statut:
epublish
Résumé
From January 18th to August 13th, 2021, 13,804 unvaccinated and 1,156 patients who had received at least one COVID-19 vaccine dose were tested qPCR-positive for SARS-CoV-2 in our center. Among vaccinated patients, 949, 205 and 2 had received a single, two or three vaccine doses, respectively. Most patients (80.3%) had received the Pfizer-BioNTech vaccine. The SARS-CoV-2 variants infecting vaccinated patients varied over time, reflecting those circulating in the Marseille area, with a predominance of the Marseille-4/20A.EU2 variant from weeks 3 to 6, of the Alpha/20I variant from weeks 7 to 25, and of the Delta/21A variant from week 26. SARS-CoV-2 infection was significantly more likely to occur in the first 13 days post-vaccine injection in those who received a single dose (48.9%) than two doses (27.4%,
Identifiants
pubmed: 35116013
doi: 10.3389/fmicb.2021.796807
pmc: PMC8803903
doi:
Types de publication
Journal Article
Langues
eng
Pagination
796807Informations de copyright
Copyright © 2022 Fournier, Houhamdi, Colson, Cortaredona, Delorme, Cassagne, Lagier, Chaudet, Tissot-Dupont, Giraud-Gatineau, Fenollar, Million and Raoult.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Travel Med Infect Dis. 2020 Jul - Aug;36:101632
pubmed: 32205269
Nature. 2021 Sep;597(7876):318-324
pubmed: 34522017
MMWR Morb Mortal Wkly Rep. 2021 Apr 02;70(13):495-500
pubmed: 33793460
Lancet. 2021 Apr 17;397(10283):1459-1469
pubmed: 33844963
Lancet. 2021 May 1;397(10285):1646-1657
pubmed: 33901420
EBioMedicine. 2021 Oct;72:103574
pubmed: 34537449
Eur J Epidemiol. 2020 Dec;35(12):1123-1138
pubmed: 33289900
Lancet. 2021 Dec 19;396(10267):1979-1993
pubmed: 33220855
MMWR Morb Mortal Wkly Rep. 2021 Sep 17;70(37):1284-1290
pubmed: 34529637
Travel Med Infect Dis. 2021 Mar-Apr;40:101980
pubmed: 33535105
Int J Infect Dis. 2021 Jul;108:1-3
pubmed: 33823281
Euro Surveill. 2021 Sep;26(37):
pubmed: 34533119
Travel Med Infect Dis. 2020 Jul - Aug;36:101791
pubmed: 32593867
Clin Microbiol Infect. 2021 Oct;27(10):1516.e1-1516.e6
pubmed: 34044152
MMWR Morb Mortal Wkly Rep. 2021 May 28;70(21):792-793
pubmed: 34043615
Lancet. 2021 May 8;397(10286):1725-1735
pubmed: 33901423
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Lancet Reg Health Am. 2021 Dec;4:100065
pubmed: 34522911
J Clin Virol. 2020 Dec;133:104682
pubmed: 33152666
Emerg Microbes Infect. 2021 Dec;10(1):2276-2278
pubmed: 34792434
Rev Cardiovasc Med. 2021 Sep 24;22(3):1063-1072
pubmed: 34565108
N Engl J Med. 2021 May 6;384(18):1774-1775
pubmed: 33755376
Infect Genet Evol. 2021 Nov;95:105092
pubmed: 34571275
N Engl J Med. 2020 Dec 17;383(25):2439-2450
pubmed: 33053279
Lancet. 2021 Mar 6;397(10277):875-877
pubmed: 33610193
N Engl J Med. 2021 Jul 22;385(4):320-329
pubmed: 34192428